BNET Industries
Market Cap:$263.3M
Last Fiscal Year Sales:$47.1M
- Public
- US
Dow Jones Description
We are a genetics company committed to providing genetic analysis products, services and diagnostic applications. Our products and services are designed to translate the results of genomic research into solutions for biomedical research, translational research, molecular medicine applications and research conducted in the agro (agricultural and livestock) industry. Our development efforts in various diagnostic applications include areas of noninvasive diagnostics in prenatal, oncology and infectious diseases and other disorders. Our proprietary MassARRAY system, comprised of hardware, software applications, consumable chips and reagents, is a high performance (in speed, accuracy and cost efficiency) nucleic acid analysis platform that quantitatively and precisely measures genetic target material and variations. Our MassARRAY research and development efforts are committed to producing new and improved components and applications that deliver greater system versatility and reduce the cost per data point generated. MassARRAY technology is widely accepted as a leading high-performance DNA analysis platform for the fine mapping genotyping and quantitative gene expression markets and is gaining traction in new developing markets, such as epigenomics and pathogen typing. Our customers include some of the worldwide premier clinical research laboratories, biotechnology companies and academic institutions, as well as various government agencies. ...
Number of Employees 248
Contact Information
3595 John Hopkins Ct
San Diego, California 92121-1331
(858) 202-9000
Peer Companies
NAICS Code : 541710
Recent Events
-
PicksThatMove.com Announces Investment Opinion on Sequenom Inc., Gabriel Resources Ltd., Rentech Inc., Imaging 3 Inc.,...
-
Sequenom Q3 Loss Widens - Update
-
Sequenom faces fraud suit from Xenomics
-
Sequenom, Ibis settle lawsuit
-
Sequenom names Maier as interim CFO
-
ATVI, RMBS, MRVL, SQNM, ERIC, AKAM With Highest Daily Short Volume On
-
Sequenom discloses probes following firings
-
Sequenom ousts CEO, other execs
-
Sequenom tumbles after execs fired amid test woes
-
Investors Remain Hopeful About Sequenom's Prospects
-
Sequenom Ousts CEO After Finding Errors, Inconsistencies In Down Syndrome Test; CFO Resigns
News & Analysis
Filter by
company and sequenom inc. - All News and Analysis
Yale University Purchases Sequenom MassARRAY Platform
SAN DIEGO -- Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis solutions, today announced the purchase by the W.M. Keck Foundation Biotechnology Resource Laboratory at Yale University of Sequenom's MassARRAY([R]) system. Yale plans to use the system as a platform for genotyping, copy number variation CNV, methylation and quantitative...
Sequenom to Begin Clinical Assessment of Noninvasive Screening Technology for Down Syndrome
Sharp HealthCare IRB Approves Study SAN DIEGO -- Sequenom, Inc. (NASDAQ:SQNM) today announced the approval of a protocol by the Institutional Review Board IRB at San Diego-based Sharp HealthCare, clearing the way to commence patient enrollment in a screening study to clinically assess the Company's noninvasive cell free fetal...
Forbes Medi-Tech to Acquire San Diego Based TheraPei Pharmaceuticals and Appoint Dr. John Nestor as Chief Scientific Officer; Acquisition will diversify the Company's Drug development pipeline; R&D to be consolidated under the direction of new CSO.
VANCOUVER, BRITISH COLUMBIA, Oct 25, 2006 CCNMatthews via COMTEX -- Forbes Medi-Tech Inc. (TSX:FMI)(NASDAQ:FMTI) today announced that it has signed an agreement to acquire 100% of TheraPei Pharmaceuticals, Inc.TheraPei of San Diego, California. TheraPei is a privately held company formed with technology 'spun-out' of Sequenom, Inc....
- 1


